Clinical trial

A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer

NCT07669779

Study summary

ClinicalTrials.gov

A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention AK146D1 for injection Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention AK112 Injection Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Platinum chemotherapy Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Osimertinib Normalized identity: osimertinib View linked drug · Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-07-10

PhasePHASE2

Conditions

Advanced Non Small Cell Lung Cancer (NSCLC)unresolved

Interventions

AK146D1 for injectionDRUG

AK112 InjectionDRUG

Platinum chemotherapyDRUG

OsimertinibDRUG · verified · RxNorm: osimertinib

Sponsors & collaborators

Akesolead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07669779 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.